Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium breve Bb-18 and Reduced Inflammation

Research synthesisLow evidenceMixed effect size4 studies · 4 beneficial · 0 neutral · 0 harmful

Across 4 studies, all reported beneficial effects of Bifidobacterium breve Bb-18 on reducing inflammation, with effect sizes ranging from small to moderate. The evidence primarily comes from a large 2025 meta-analysis in subjects with type 2 diabetes mellitus (n=3390), showing small beneficial effects on inflammatory markers such as high-sensitivity C-reactive protein and tumor necrosis factor alpha. No consistent dose range or study duration was reported across the studies.

  • Studied populations: subjects with type 2 diabetes mellitus, pregnant women with gestational diabetes mellitus, healthy adults

Caveats: Evidence base is small (only 4 studies) — conclusions should be considered preliminary. None of the studies reported statistical significance for the specific effect of Bifidobacterium breve Bb-18 on inflammation, as the supplement was often part of multi-strain or synbiotic formulations. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed).

Generated Jun 11, 2026
4 of 4 papers
Back to top